Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Voluven

&times

Overview

What is Voluven?

Voluven (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection) is a clear to slightly opalescent, colorless to slightly yellow, sterile, non-pyrogenic, isotonic solution for intravenous administration using sterile equipment.

Each 100 mL of the solution contains: 6 g of Hydroxyethyl Starch 130/0.4 and 900 mg of Sodium Chloride USP in Water for Injection USP.

In addition, sodium hydroxide, USP, or Hydrochloric acid, USP, has been added to adjust the final pH so the final solution pH is 4.0 to 5.5.

The electrolyte composition is as follows (mEq/L): Sodium 154, Chloride 154.

The calculated osmolarity is 308 mOsmol/L.

The hydroxyethyl starch contained in Voluven is a synthetic colloid for use in plasma volume replacement. The chemical name of hydroxyethyl starch is poly(O-2-hydroxyethyl) starch. The structural formula of hydroxyethyl starch is

    

Voluven is packaged in 500 mL flexible plastic containers ( ). is a flexible container made from coextruded polyolefin and is free of PVC, plasticizers, adhesives or latex (Non-DEHP, Latex-free). The container offers an air-closed system and can be used with non-vented IV sets which prevent external air contamination. is collapsible and can be used in emergency cases for pressure infusion.



What does Voluven look like?



What are the available doses of Voluven?

500 mL flexible plastic intravenous solution container. Each 100 mL contains 6 g hydroxyethyl starch 130/0.4 in isotonic sodium chloride injection. ()

What should I talk to my health care provider before I take Voluven?

How should I use Voluven?

Voluven (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection) is indicated for the treatment and prophylaxis of hypovolemia in adults and children. It is not a substitute for red blood cells or coagulation factors in plasma.

Voluven is administered by intravenous infusion only. 

The initial 10 to 20 mL should be infused slowly, keeping the patient under close observation due to possible anaphylactoid reactions. [see ]


What interacts with Voluven?

Sorry No Records found


What are the warnings of Voluven?

Sorry No Records found


What are the precautions of Voluven?

Sorry No Records found


What are the side effects of Voluven?

Sorry No records found


What should I look out for while using Voluven?

Do not use hydroxyethyl starch (HES) products, including Voluven, in critically ill adult patients, including patients with sepsis due to increased risk of mortality and renal replacement therapy. ()

Do not use HES products, including Voluven, in patients with severe liver disease. ()

Do not use HES products, including Voluven, in patients with known hypersensitivity to hydroxyethyl starch. ()

Do not use HES products in clinical conditions with volume overload. ()

Do not use HES products in patients with pre-existing coagulation or bleeding disorders. ()

Do not use HES products in patients with renal failure with oliguria or anuria not related to hypovolemia. ()

Do not use HES products in patients receiving dialysis. ()

Do not use HES products in patients with severe hypernatremia or severe hyperchloremia. ()

Do not use HES products in patients with intracranial bleeding. ()


What might happen if I take too much Voluven?

Overdosage can lead to overloading of the circulatory system (e.g., pulmonary edema). In this case, the infusion should be stopped immediately and if necessary, a diuretic should be administered. [see ]


How should I store and handle Voluven?

Minocycline hydrochloride tablets USP are supplied as aqueous film coated tablets containing minocycline hydrochloride equivalent to 50 mg, 75 mg and 100 mg minocycline. The 50 mg tablets are yellow, round, biconvex, film coated tablets debossed “I71" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 50 mg minocycline, supplied as follows: (NDC 55111-637-01) Bottle of 100(NDC 55111-637-10) Bottle of 1000 The 75 mg tablets are grey, round, biconvex, film coated tablets debossed “I72" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 75 mg minocycline, supplied as follows:(NDC 55111-638-01) Bottle of 100(NDC 55111-638-10) Bottle of 1000 The 100 mg tablets are dark grey, round, biconvex, film coated tablets debossed “I73" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 100 mg minocycline, supplied as follows:(NDC 55111-639-50) Bottle of 50(NDC 55111-639-60) Bottle of 60(NDC 55111-639-10) Bottle of 1000  Store between 20º-25ºC (68º-77ºF) [See USP Controlled Room Temperature].Protect from light, moisture and excessive heat.Dispense in a tight, light-resistant container as defined in the USP.Minocycline hydrochloride tablets USP are supplied as aqueous film coated tablets containing minocycline hydrochloride equivalent to 50 mg, 75 mg and 100 mg minocycline. The 50 mg tablets are yellow, round, biconvex, film coated tablets debossed “I71" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 50 mg minocycline, supplied as follows: (NDC 55111-637-01) Bottle of 100(NDC 55111-637-10) Bottle of 1000 The 75 mg tablets are grey, round, biconvex, film coated tablets debossed “I72" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 75 mg minocycline, supplied as follows:(NDC 55111-638-01) Bottle of 100(NDC 55111-638-10) Bottle of 1000 The 100 mg tablets are dark grey, round, biconvex, film coated tablets debossed “I73" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 100 mg minocycline, supplied as follows:(NDC 55111-639-50) Bottle of 50(NDC 55111-639-60) Bottle of 60(NDC 55111-639-10) Bottle of 1000  Store between 20º-25ºC (68º-77ºF) [See USP Controlled Room Temperature].Protect from light, moisture and excessive heat.Dispense in a tight, light-resistant container as defined in the USP.Minocycline hydrochloride tablets USP are supplied as aqueous film coated tablets containing minocycline hydrochloride equivalent to 50 mg, 75 mg and 100 mg minocycline. The 50 mg tablets are yellow, round, biconvex, film coated tablets debossed “I71" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 50 mg minocycline, supplied as follows: (NDC 55111-637-01) Bottle of 100(NDC 55111-637-10) Bottle of 1000 The 75 mg tablets are grey, round, biconvex, film coated tablets debossed “I72" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 75 mg minocycline, supplied as follows:(NDC 55111-638-01) Bottle of 100(NDC 55111-638-10) Bottle of 1000 The 100 mg tablets are dark grey, round, biconvex, film coated tablets debossed “I73" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 100 mg minocycline, supplied as follows:(NDC 55111-639-50) Bottle of 50(NDC 55111-639-60) Bottle of 60(NDC 55111-639-10) Bottle of 1000  Store between 20º-25ºC (68º-77ºF) [See USP Controlled Room Temperature].Protect from light, moisture and excessive heat.Dispense in a tight, light-resistant container as defined in the USP.Minocycline hydrochloride tablets USP are supplied as aqueous film coated tablets containing minocycline hydrochloride equivalent to 50 mg, 75 mg and 100 mg minocycline. The 50 mg tablets are yellow, round, biconvex, film coated tablets debossed “I71" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 50 mg minocycline, supplied as follows: (NDC 55111-637-01) Bottle of 100(NDC 55111-637-10) Bottle of 1000 The 75 mg tablets are grey, round, biconvex, film coated tablets debossed “I72" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 75 mg minocycline, supplied as follows:(NDC 55111-638-01) Bottle of 100(NDC 55111-638-10) Bottle of 1000 The 100 mg tablets are dark grey, round, biconvex, film coated tablets debossed “I73" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 100 mg minocycline, supplied as follows:(NDC 55111-639-50) Bottle of 50(NDC 55111-639-60) Bottle of 60(NDC 55111-639-10) Bottle of 1000  Store between 20º-25ºC (68º-77ºF) [See USP Controlled Room Temperature].Protect from light, moisture and excessive heat.Dispense in a tight, light-resistant container as defined in the USP.Minocycline hydrochloride tablets USP are supplied as aqueous film coated tablets containing minocycline hydrochloride equivalent to 50 mg, 75 mg and 100 mg minocycline. The 50 mg tablets are yellow, round, biconvex, film coated tablets debossed “I71" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 50 mg minocycline, supplied as follows: (NDC 55111-637-01) Bottle of 100(NDC 55111-637-10) Bottle of 1000 The 75 mg tablets are grey, round, biconvex, film coated tablets debossed “I72" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 75 mg minocycline, supplied as follows:(NDC 55111-638-01) Bottle of 100(NDC 55111-638-10) Bottle of 1000 The 100 mg tablets are dark grey, round, biconvex, film coated tablets debossed “I73" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 100 mg minocycline, supplied as follows:(NDC 55111-639-50) Bottle of 50(NDC 55111-639-60) Bottle of 60(NDC 55111-639-10) Bottle of 1000  Store between 20º-25ºC (68º-77ºF) [See USP Controlled Room Temperature].Protect from light, moisture and excessive heat.Dispense in a tight, light-resistant container as defined in the USP.Minocycline hydrochloride tablets USP are supplied as aqueous film coated tablets containing minocycline hydrochloride equivalent to 50 mg, 75 mg and 100 mg minocycline. The 50 mg tablets are yellow, round, biconvex, film coated tablets debossed “I71" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 50 mg minocycline, supplied as follows: (NDC 55111-637-01) Bottle of 100(NDC 55111-637-10) Bottle of 1000 The 75 mg tablets are grey, round, biconvex, film coated tablets debossed “I72" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 75 mg minocycline, supplied as follows:(NDC 55111-638-01) Bottle of 100(NDC 55111-638-10) Bottle of 1000 The 100 mg tablets are dark grey, round, biconvex, film coated tablets debossed “I73" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 100 mg minocycline, supplied as follows:(NDC 55111-639-50) Bottle of 50(NDC 55111-639-60) Bottle of 60(NDC 55111-639-10) Bottle of 1000  Store between 20º-25ºC (68º-77ºF) [See USP Controlled Room Temperature].Protect from light, moisture and excessive heat.Dispense in a tight, light-resistant container as defined in the USP.Minocycline hydrochloride tablets USP are supplied as aqueous film coated tablets containing minocycline hydrochloride equivalent to 50 mg, 75 mg and 100 mg minocycline. The 50 mg tablets are yellow, round, biconvex, film coated tablets debossed “I71" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 50 mg minocycline, supplied as follows: (NDC 55111-637-01) Bottle of 100(NDC 55111-637-10) Bottle of 1000 The 75 mg tablets are grey, round, biconvex, film coated tablets debossed “I72" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 75 mg minocycline, supplied as follows:(NDC 55111-638-01) Bottle of 100(NDC 55111-638-10) Bottle of 1000 The 100 mg tablets are dark grey, round, biconvex, film coated tablets debossed “I73" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 100 mg minocycline, supplied as follows:(NDC 55111-639-50) Bottle of 50(NDC 55111-639-60) Bottle of 60(NDC 55111-639-10) Bottle of 1000  Store between 20º-25ºC (68º-77ºF) [See USP Controlled Room Temperature].Protect from light, moisture and excessive heat.Dispense in a tight, light-resistant container as defined in the USP.Minocycline hydrochloride tablets USP are supplied as aqueous film coated tablets containing minocycline hydrochloride equivalent to 50 mg, 75 mg and 100 mg minocycline. The 50 mg tablets are yellow, round, biconvex, film coated tablets debossed “I71" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 50 mg minocycline, supplied as follows: (NDC 55111-637-01) Bottle of 100(NDC 55111-637-10) Bottle of 1000 The 75 mg tablets are grey, round, biconvex, film coated tablets debossed “I72" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 75 mg minocycline, supplied as follows:(NDC 55111-638-01) Bottle of 100(NDC 55111-638-10) Bottle of 1000 The 100 mg tablets are dark grey, round, biconvex, film coated tablets debossed “I73" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 100 mg minocycline, supplied as follows:(NDC 55111-639-50) Bottle of 50(NDC 55111-639-60) Bottle of 60(NDC 55111-639-10) Bottle of 1000  Store between 20º-25ºC (68º-77ºF) [See USP Controlled Room Temperature].Protect from light, moisture and excessive heat.Dispense in a tight, light-resistant container as defined in the USP.Minocycline hydrochloride tablets USP are supplied as aqueous film coated tablets containing minocycline hydrochloride equivalent to 50 mg, 75 mg and 100 mg minocycline. The 50 mg tablets are yellow, round, biconvex, film coated tablets debossed “I71" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 50 mg minocycline, supplied as follows: (NDC 55111-637-01) Bottle of 100(NDC 55111-637-10) Bottle of 1000 The 75 mg tablets are grey, round, biconvex, film coated tablets debossed “I72" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 75 mg minocycline, supplied as follows:(NDC 55111-638-01) Bottle of 100(NDC 55111-638-10) Bottle of 1000 The 100 mg tablets are dark grey, round, biconvex, film coated tablets debossed “I73" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 100 mg minocycline, supplied as follows:(NDC 55111-639-50) Bottle of 50(NDC 55111-639-60) Bottle of 60(NDC 55111-639-10) Bottle of 1000  Store between 20º-25ºC (68º-77ºF) [See USP Controlled Room Temperature].Protect from light, moisture and excessive heat.Dispense in a tight, light-resistant container as defined in the USP.Minocycline hydrochloride tablets USP are supplied as aqueous film coated tablets containing minocycline hydrochloride equivalent to 50 mg, 75 mg and 100 mg minocycline. The 50 mg tablets are yellow, round, biconvex, film coated tablets debossed “I71" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 50 mg minocycline, supplied as follows: (NDC 55111-637-01) Bottle of 100(NDC 55111-637-10) Bottle of 1000 The 75 mg tablets are grey, round, biconvex, film coated tablets debossed “I72" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 75 mg minocycline, supplied as follows:(NDC 55111-638-01) Bottle of 100(NDC 55111-638-10) Bottle of 1000 The 100 mg tablets are dark grey, round, biconvex, film coated tablets debossed “I73" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 100 mg minocycline, supplied as follows:(NDC 55111-639-50) Bottle of 50(NDC 55111-639-60) Bottle of 60(NDC 55111-639-10) Bottle of 1000  Store between 20º-25ºC (68º-77ºF) [See USP Controlled Room Temperature].Protect from light, moisture and excessive heat.Dispense in a tight, light-resistant container as defined in the USP.Minocycline hydrochloride tablets USP are supplied as aqueous film coated tablets containing minocycline hydrochloride equivalent to 50 mg, 75 mg and 100 mg minocycline. The 50 mg tablets are yellow, round, biconvex, film coated tablets debossed “I71" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 50 mg minocycline, supplied as follows: (NDC 55111-637-01) Bottle of 100(NDC 55111-637-10) Bottle of 1000 The 75 mg tablets are grey, round, biconvex, film coated tablets debossed “I72" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 75 mg minocycline, supplied as follows:(NDC 55111-638-01) Bottle of 100(NDC 55111-638-10) Bottle of 1000 The 100 mg tablets are dark grey, round, biconvex, film coated tablets debossed “I73" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 100 mg minocycline, supplied as follows:(NDC 55111-639-50) Bottle of 50(NDC 55111-639-60) Bottle of 60(NDC 55111-639-10) Bottle of 1000  Store between 20º-25ºC (68º-77ºF) [See USP Controlled Room Temperature].Protect from light, moisture and excessive heat.Dispense in a tight, light-resistant container as defined in the USP.Minocycline hydrochloride tablets USP are supplied as aqueous film coated tablets containing minocycline hydrochloride equivalent to 50 mg, 75 mg and 100 mg minocycline. The 50 mg tablets are yellow, round, biconvex, film coated tablets debossed “I71" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 50 mg minocycline, supplied as follows: (NDC 55111-637-01) Bottle of 100(NDC 55111-637-10) Bottle of 1000 The 75 mg tablets are grey, round, biconvex, film coated tablets debossed “I72" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 75 mg minocycline, supplied as follows:(NDC 55111-638-01) Bottle of 100(NDC 55111-638-10) Bottle of 1000 The 100 mg tablets are dark grey, round, biconvex, film coated tablets debossed “I73" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 100 mg minocycline, supplied as follows:(NDC 55111-639-50) Bottle of 50(NDC 55111-639-60) Bottle of 60(NDC 55111-639-10) Bottle of 1000  Store between 20º-25ºC (68º-77ºF) [See USP Controlled Room Temperature].Protect from light, moisture and excessive heat.Dispense in a tight, light-resistant container as defined in the USP.Minocycline hydrochloride tablets USP are supplied as aqueous film coated tablets containing minocycline hydrochloride equivalent to 50 mg, 75 mg and 100 mg minocycline. The 50 mg tablets are yellow, round, biconvex, film coated tablets debossed “I71" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 50 mg minocycline, supplied as follows: (NDC 55111-637-01) Bottle of 100(NDC 55111-637-10) Bottle of 1000 The 75 mg tablets are grey, round, biconvex, film coated tablets debossed “I72" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 75 mg minocycline, supplied as follows:(NDC 55111-638-01) Bottle of 100(NDC 55111-638-10) Bottle of 1000 The 100 mg tablets are dark grey, round, biconvex, film coated tablets debossed “I73" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 100 mg minocycline, supplied as follows:(NDC 55111-639-50) Bottle of 50(NDC 55111-639-60) Bottle of 60(NDC 55111-639-10) Bottle of 1000  Store between 20º-25ºC (68º-77ºF) [See USP Controlled Room Temperature].Protect from light, moisture and excessive heat.Dispense in a tight, light-resistant container as defined in the USP.Minocycline hydrochloride tablets USP are supplied as aqueous film coated tablets containing minocycline hydrochloride equivalent to 50 mg, 75 mg and 100 mg minocycline. The 50 mg tablets are yellow, round, biconvex, film coated tablets debossed “I71" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 50 mg minocycline, supplied as follows: (NDC 55111-637-01) Bottle of 100(NDC 55111-637-10) Bottle of 1000 The 75 mg tablets are grey, round, biconvex, film coated tablets debossed “I72" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 75 mg minocycline, supplied as follows:(NDC 55111-638-01) Bottle of 100(NDC 55111-638-10) Bottle of 1000 The 100 mg tablets are dark grey, round, biconvex, film coated tablets debossed “I73" on one side and plain on the other. Each tablet contains minocycline hydrochloride equivalent to 100 mg minocycline, supplied as follows:(NDC 55111-639-50) Bottle of 50(NDC 55111-639-60) Bottle of 60(NDC 55111-639-10) Bottle of 1000  Store between 20º-25ºC (68º-77ºF) [See USP Controlled Room Temperature].Protect from light, moisture and excessive heat.Dispense in a tight, light-resistant container as defined in the USP.


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Voluven contains hydroxyethyl starch in a colloidal solution which expands plasma volume when administered intravenously. This effect depends on the mean molecular weight (130,000 daltons; range 110,000 – 150,000 daltons), the molar substitution by hydroxyethyl groups (0.4; range 0.38 – 0.45) on glucose units of the starch, the pattern of hydroxyethyl substitution (C/C ratio) of approximately 9:1, and the concentration (6%), as well as the dosage and infusion rate.

Hydroxyethyl starch is a derivative of thin boiling waxy corn starch, which mainly consists of a glucose polymer (amylopectin) predominantly composed of α-1-4-connected glucose units with several α-1-6-branches. Substitution of hydroxyethyl groups on the glucose units of the polymer reduces the normal degradation of amylopectin by α-amylase in the body. The low molar substitution (0.4) is the main pharmacological determinant for the beneficial effects of Voluven on pharmacokinetics, intravascular volume and hemodilution. To describe the molecular weight and molar substitution characteristics of the hydroxyethyl starch in Voluven, the compound is designated as hydroxyethyl starch 130/0.4.

Non-Clinical Toxicology
Do not use hydroxyethyl starch (HES) products, including Voluven, in critically ill adult patients, including patients with sepsis due to increased risk of mortality and renal replacement therapy. ()

Do not use HES products, including Voluven, in patients with severe liver disease. ()

Do not use HES products, including Voluven, in patients with known hypersensitivity to hydroxyethyl starch. ()

Do not use HES products in clinical conditions with volume overload. ()

Do not use HES products in patients with pre-existing coagulation or bleeding disorders. ()

Do not use HES products in patients with renal failure with oliguria or anuria not related to hypovolemia. ()

Do not use HES products in patients receiving dialysis. ()

Do not use HES products in patients with severe hypernatremia or severe hyperchloremia. ()

Do not use HES products in patients with intracranial bleeding. ()

Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.

Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin.

Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.

The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.

Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.

Administration of isotretinoin should be avoided shortly before, during, and shortly after minocycline therapy. Each drug alone has been associated with pseudotumor cerebri (see ). 

Increased risk of ergotism when ergot alkaloids or their derivatives are given with tetracyclines. 

Anaphylactoid reactions (mild influenza-like symptoms, bradycardia, tachycardia, bronchospasm, non-cardiac pulmonary edema) have been reported with solutions containing hydroxyethyl starch. If a hypersensitivity reaction occurs, administration of the drug should be discontinued immediately and the appropriate treatment and supportive measures should be undertaken until symptoms have resolved. [see ]

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).